Skip to main content

Advertisement

Table 1 Cochrane review data used as the basis for this analysis

From: Rational choice of cholinesterase inhibitor for the treatment of Alzheimer's disease in Canada: a comparative economic analysis

  Donepezil Rivastigmine Galantamine
Daily dose 5 mg 10 mg 1–4 mg 6–12 mg 16 mg 24 mg
Efficacy* -1.86 -2.90 -0.84 -2.09 -3.10 -3.29
   95% CI -2.60, -1.11 -3.65,-2.16 -1.48, -0.19 -2.65, -1.54 -4.13, -2.07 -3.92, -2.65
Beta -0.071 -0.106 -0.036 -0.091 -0.105 -0.124
   95% CI -0.099, -0.042 -0.133, -0.079 -0.067, -0.008 -0.115, -0.067 -0.14 -0.070 -0.147, -0.100
Withdrawal 1.02 1.36 1.01 1.95 1.34 1.51
   95% CI 0.78, 1.33 1.10,1.70 0.80, 1.27 1.65, 2.32 0.95, 1.89 1.23, 1.87
  1. * measured in terms of the weighted difference in mean cognitive change on the ADAS-cog comparing treatment to placebo coefficient for variable effect analysis calculated as the efficacy divided by the mean baseline score relative risk of withdrawing from treatment, compared to placebo patients